List view / Grid view


First patient enrolled in the New Drugs 4 Bad Bugs (ND4BB) programme

3 February 2015 | By Innovative Medicines Initiative (IMI)

Two years after the start of the Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) programme, the first patient has been enrolled into a Phase 2 trial sponsored by MedImmune, the global biologics research and development arm of AstraZeneca. The trial with MEDI4893 is among mechanically ventilated intubated…

Genticel business update – fourth quarter 2014

28 January 2015 | By Genticel

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, announces its cash ans cash equivalents and liquid investments position and its highlights from the fourth quarter of 2014...